Pluristyx and panCELLa Expand Intellectual Property Portfolio
12 Jan 2023 //
BUSINESSWIRE
Pluristyx, panCELLa, & Implant Therapeutics Announce Definitive Merger Agreement
06 Oct 2022 //
BUSINESSWIRE
Merck licenses CRISPR genome-editing technology to PanCELLa and Takara Bio
13 Oct 2020 //
PHARMABIZ

Market Place
Sourcing Support